[Asia Economy Reporter Lim Jeong-su] Philosis Healthcare announced on the 25th that it has received export approval from the Ministry of Food and Drug Safety for the antigen rapid diagnostic kit ‘Gmate COVID-19 Ag’.
According to Philosis Healthcare, Gmate COVID-19 is simple to use as it measures saliva. Additionally, it is known to have high utility as results can be read and transmitted via an application (App).
This diagnostic kit is currently produced by the group affiliate Philosci and sold by Philosis Healthcare. Recently, it demonstrated 95% accuracy at a hospital under the Malaysian Ministry of Health, leading to an export contract with Malaysia.
With this export approval, full-scale exports of Gmate COVID-19 are expected to commence.
A Philosis Healthcare official stated, "On the day of export approval, the 21st, 600,000 units were shipped, and approximately 1.5 million units are scheduled to be shipped by February," adding, "We are also negotiating export contracts with European countries such as Romania and Greece."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
